Press Releases
Filter By Year
May
April
-
April 29, 2021
Gilead Sciences Announces Second Quarter 2021 Dividend -
April 29, 2021
Gilead Sciences Announces First Quarter 2021 Financial Results -
April 26, 2021
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India -
April 15, 2021
Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021 -
April 13, 2021
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer -
April 07, 2021
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival -
April 01, 2021
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
March
-
March 31, 2021
Gilead Sciences Comments on the Passing of John C. Martin, PhD -
March 26, 2021
Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research -
March 25, 2021
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer -
March 18, 2021
Gilead and Novo Nordisk Expand NASH Clinical Collaboration -
March 15, 2021
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV -
March 09, 2021
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI -
March 06, 2021
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI -
March 05, 2021
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy -
March 04, 2021
Gilead Sciences Completes Acquisition of MYR GmbH -
March 02, 2021
Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
February
-
February 18, 2021
Gilead Sciences to Present at Upcoming Investor Conferences -
February 16, 2021
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach -
February 10, 2021
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma -
February 10, 2021
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF -
February 08, 2021
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development -
February 04, 2021
Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend -
February 04, 2021
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results -
February 02, 2021
Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice -
February 01, 2021
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
January
-
January 21, 2021
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021 -
January 19, 2021
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research -
January 12, 2021
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus -
January 11, 2021
Gilead Sciences Announces Updated 2020 Guidance -
January 06, 2021
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
Filter By Year